The Technical Analyst
Twist Bioscience Corp [TWST]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Twist Bioscience Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-2.38% $30.75
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 757.27 mill |
| EPS: | -3.99 |
| P/E: | -7.71 |
| Earnings Date: | Aug 03, 2023 |
| SharesOutstanding: | 57.15 mill |
| Avg Daily Volume: | 0.886 mill |
| RATING 2024-04-24 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -7.71 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.41x |
| Company: PE -7.71 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 28.80 - 32.70 ( +/- 6.33%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-09 | Laponis Adam | Sell | 556 | Common Stock |
| 2024-04-02 | Finn Patrick John | Sell | 492 | Common Stock |
| 2024-04-02 | Banyai William | Sell | 327 | Common Stock |
| 2024-04-02 | Leproust Emily M. | Sell | 1 132 | Common Stock |
| 2024-04-02 | Cho Dennis | Sell | 129 | Common Stock |
| INSIDER POWER |
|---|
| 81.09 |
| Last 100 transactions |
| Buy: 775 183 | Sell: 76 049 |
Forecast:
16:00 - $30.78
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $30.78
Forecast 2: 16:00 - $30.78
Forecast 3: 16:00 - $30.78
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $30.75 (-2.38% ) |
| Volume | 1.402 mill |
| Avg. Vol. | 0.886 mill |
| % of Avg. Vol | 158.29 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TWST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $36.80 | N/A | Active |
|---|
TWST
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Latest Press Releases
2024-04-18 08:00:00 - Press Release
Twist Bioscience To Report Fiscal 2024 Second Quarter Financial Results On Thursday, May 2, 2024
South san francisco, calif.--(business wire)--twist bioscience corporation (nasdaq: twst), a company enabling customers to succeed through its offering of high-quality synthetic dna using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 second quarter ended march 31, 2024, after market close on thursday, may 2, 2024. the company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. eastern time to discuss.
2024-03-28 08:00:00 - Press Release
Twist Bioscience Launches Pangenome Spike-in Exome Panel To Enable Advancement Of Research For Diverse Populations
South san francisco, calif.--(business wire)--twist bioscience corporation (nasdaq: twst), a company enabling customers to succeed through its offering of high-quality synthetic dna using its silicon platform, today announced the launch of a new human pangenome spike-in for the twist exome 2.0 panel developed to enable researchers to detect a more complete view of genetic variation during whole exome sequencing (wes). “no one single human genome can serve as a reference representing everyone. i.
2024-03-05 08:00:00 - Press Release
Twist Bioscience Launches Ivdr-compliant Precision Dx Products For Whole Exome Sequencing
South san francisco, calif.--(business wire)--twist bioscience corporation (nasdaq: twst), a company enabling customers to succeed through its offering of high-quality synthetic dna using its silicon platform, today announced european union (eu) in vitro diagnostic regulations (ivdr) compliant twist precision dx next-generation sequencing (ngs) products. in accordance with the ivd regulations put in place by the eu to ensure the safety and quality of in vitro diagnostic medical devices, twist's.
2024-02-07 08:00:00 - Press Release
Twist Bioscience Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
South san francisco, calif.--(business wire)--as required by the rules of the nasdaq stock market, twist bioscience corporation (nasdaq: twst) (“twist” or the “company”), a company enabling customers to succeed through its offering of high-quality synthetic dna using its silicon platform, today announced that it has granted a total of 122,400 restricted stock units (“rsus”) to 36 recently hired individuals as an inducement material to their acceptance of employment with twist. the employment in.
2024-02-06 08:05:00 - Press Release
Twist Bioscience And Element Biosciences Collaborate On Exome Sequencing Solutions For Aviti System
South san francisco, calif. & san diego--(business wire)--twist bioscience corporation (nasdaq: twst), a company enabling customers to succeed through its offering of high-quality synthetic dna using its silicon platform, and element biosciences, inc., developer of pioneering technologies to empower science, today announced a collaboration to develop the twist for element, exome 2.0 plus comprehensive exome spike-in workflow for element's aviti™ system. “element continues to expand its customer.
Latest News
2024-04-18 08:00:00 - Business Wire
Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, after market close on Thursday, May 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss.
2024-02-13 13:59:53 - InvestorPlace
7 Stocks Cathie Wood Is Still Loading Up On in Q1
You can't say Cathie Wood is afraid to make big bets. The investing guru is more than willing to lay it all on the line for stocks she believes in.
2024-02-11 15:44:58 - InvestorPlace
7 Sexy Stocks That Will Continue to Outperform in 2024
While 2023 was the year of the Magnificent Seven, the seven outperforming stocks in this article are likely to be winners that will surge past the broader indices, such as the S&P 500 and the Nasdaq. The reason is that these companies trade at low valuations and have robust outlooks for this year and beyond.
2024-02-07 09:22:26 - Seeking Alpha
Twist Bioscience: Strong Performance In A Soft Market
Twist Bioscience reported strong results in the first quarter of FY2024, despite a tepid demand environment. Growth was somewhat exaggerated by lumpy NGS revenue, but overall the business is progressing well, particularly from a profitability perspective. Twist's share price has increased significantly in recent months, which probably means that near-term upside is limited.
2024-02-02 13:11:04 - Seeking Alpha
Twist Bioscience Corporation (TWST) Q1 2024 Earnings Call Transcript
2023-12-19 12:44:57 - InvestorPlace
3 Genomics Stocks to Unlock the Future of Medicine
Genomics is undeniably medicine's future, and genomics stocks stand to be the next big thing in healthcare as the industry matures. But the crux of the matter is when the industry will mature.
2023-12-15 09:46:54 - Zacks Investment Research
Twist Bioscience (TWST) Soars 12.5%: Is Further Upside Left in the Stock?
Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
2023-12-01 12:53:38 - Zacks Investment Research
5 Best Performing Stocks of the Top ETF of November
ARK Innovation ETF (ARKK), which provides thematic multi-cap exposure to innovation across sectors, has gained 35.2%, becoming the best-performing ETF of November.
2023-11-17 09:46:12 - Zacks Investment Research
Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.94. This compares to loss of $0.91 per share a year ago.
2023-11-02 16:55:06 - Seeking Alpha
A New Look At Twist Bioscience
Today, we take a look synthetic biology company Twist Bioscience Corporation for the first time since spring. The company recently signed collaboration deals with two new drugmakers and saw upward analyst price target revisions after strong Q2 results.